Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.18B | $3.25B | $1.72B | $1.78B | $1.73B | $1.91B | $1.97B | $1.99B | $2.01B | $1.91B |
| Revenue growth | — | 2.2% | -47.0% | 3.3% | -2.6% | 10.2% | 3.2% | 1.1% | 0.9% | -4.9% |
| Operating income | $572M | $455M | $248M | $172M | $98.1M | $203M | $173M | $7.32M | -$68.7M | $209M |
| Operating margin | 18.0% | 14.0% | 14.4% | 9.7% | 5.7% | 10.6% | 8.8% | 0.4% | -3.4% | 10.9% |
| Net income | $325M | $320M | $269M | -$1.50B | -$796M | $131M | $66.3M | -$60.4M | -$99.1M | $165M |
| Net margin | 10.2% | 9.8% | 15.6% | -84.2% | -45.9% | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% |
| EPS (diluted) | $3.49 | $3.45 | $2.93 | -$17.83 | -$9.55 | $1.53 | $0.79 | -$0.73 | -$1.19 | $1.94 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $444M | $511M | $314M | $358M | $205M | $76.7M | $167M | $137M | $207M | $271M |
| Share buybacks | $61.8M | $70.2M | $302M | $145M | $8.49M | $4.72M | $88.5M | $919K | $1.70M | $86.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $55.7M | $40.4M | $40.8M | $108M | $1.12B | $387M | $9.82M | $73.3M | $230M | $375M |
| Total assets | $5.34B | $5.87B | $5.94B | $4.15B | $3.35B | $2.72B | $2.35B | $2.22B | $2.15B | $2.25B |
| Total liabilities | $2.58B | $2.80B | $2.85B | $2.65B | $2.60B | $1.83B | $1.46B | $1.37B | $1.39B | $1.38B |
| Long-term debt | $1.70B | $1.85B | $1.97B | $1.70B | $1.70B | $990M | $637M | $622M | $611M | — |
| Shareholders' equity | $2.76B | $3.07B | $3.09B | $1.50B | $747M | $896M | $892M | $849M | $765M | $866M |
| Retained earnings | $1.79B | $2.05B | $2.09B | $510M | -$286M | -$155M | -$89.1M | -$149M | -$249M | -$83.2M |
| Shares (wtd avg diluted) | 93.1M | 93.0M | 91.6M | 84.0M | 83.4M | 85.8M | 84.1M | 82.2M | 83.3M | 85.3M |
Every figure is extracted from Pediatrix Medical Group, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.